Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $20.00

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $20.00.

Several brokerages have weighed in on ENTA. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. JPMorgan Chase & Co. dropped their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $11.07 on Wednesday. The firm has a market cap of $234.57 million, a price-to-earnings ratio of -2.03 and a beta of 0.56. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $17.80. The firm has a fifty day moving average price of $11.55 and a two-hundred day moving average price of $12.65.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Farallon Capital Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 3.5% during the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after acquiring an additional 70,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares during the period. Acadian Asset Management LLC grew its holdings in Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after buying an additional 10,952 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Enanta Pharmaceuticals by 13.3% during the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock worth $958,000 after buying an additional 8,645 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 18,003 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.